Cytarabine-Induced Bradycardia: A Case Report

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Cardiotoxicity is a significant concern with chemotherapy, potentially leading to serious cardiac events.
• Common chemotherapeutic agents like taxanes and cisplatin are known to induce cardiotoxicity.
• Cardiac complications include arrhythmias, cardiomyopathy, and cardiac arrest, necessitating careful patient monitoring.

Observation:

• This report details a patient who developed severe symptomatic bradycardia.
• The bradycardia occurred after the administration of idarubicin and cytarabine.
• The patient's condition was managed conservatively.

Findings:

• Idarubicin and cytarabine can cause severe symptomatic bradycardia as a form of cardiotoxicity.
• Conservative management can be effective for chemotherapy-induced bradycardia.
• A literature review supports the understanding of this specific cardiotoxic effect.

Implications:

• Clinicians should be vigilant for cardiotoxicity, specifically bradycardia, in patients receiving idarubicin and cytarabine.
• Conservative management strategies may be appropriate for certain cases of chemotherapy-induced bradycardia.
• Further research into the mechanisms and management of cardiotoxicity from specific chemotherapeutic agents is warranted.